Liver Fibrosis Model
Creative Bioarray provides liver fibrosis animal models for preclinical drug discovery, efficacy evaluation, and translational liver disease research. Our platform includes chemical-induced, and surgery-induced models for anti-fibrotic drug development.
Background of Liver Fibrosis
Liver fibrosis is a gradual wound-healing response to chronic liver injury caused by metabolic dysfunction, viral infection, alcohol consumption, cholestasis, or chemical damage. With the expanding epidemic of MASLD/MASH, fibrosis is the leading cause of cirrhosis, liver failure and hepatocellular cancer.
Persistent liver injury triggers hepatocyte apoptosis and inflammatory activation, leading to Kupffer cell recruitment and cytokine release. These signals activate hepatic stellate cells (HSCs), which transdifferentiate into collagen-producing myofibroblasts, resulting in excessive extracellular matrix (ECM) deposition and architectural distortion of liver tissue.
Fig. 1. Pathogenesis of hepatic fibrosis (Weiskirchen R, Weiskirchen S, et al. 2018).
Key regulatory pathways include TGF-β/SMAD signaling, NF-κB-mediated inflammation, oxidative stress, and gut–liver axis dysregulation. Despite advances in supportive care, there is still no broadly effective anti-fibrotic therapy approved, and many late-stage clinical candidates have failed due to poor translational predictability.
Therefore, physiologically relevant liver fibrosis animal models are essential for efficacy validation, mechanism studies, biomarker discovery, and translational drug development.
Creative Bioarray's Liver Fibrosis Models
CCl4-Induced Liver Fibrosis Model
CCl4 is metabolized by hepatic CYP450 enzymes into reactive free radicals, inducing hepatocyte necrosis, oxidative stress, inflammatory activation, and hepatic stellate cell (HSC) activation. Repeated administration results in robust and reproducible liver fibrosis and is widely used for anti-fibrotic drug evaluation.
Thioacetamide (TAA)-Induced Liver Fibrosis Model
TAA induces chronic hepatotoxicity through oxidative stress and inflammatory injury, leading to progressive periportal fibrosis and cirrhosis. This model is commonly used for long-term fibrosis progression and cirrhosis studies.
Bile Duct Ligation (BDL) Model
BDL is a surgical model of cholestatic liver injury. Bile duct obstruction causes bile acid accumulation, portal inflammation, ductular proliferation, and periportal fibrosis, making this model particularly useful for cholestatic fibrosis research.
Model Comparison Overview
| Model Type | Model | Induction Method | Disease Features | Time to Fibrosis | Primary Application |
| Chemical | CCl4 | Chemical toxin (CYP450 activation) | Rapid fibrosis, strong necroinflammation | 6–8 weeks | Drug efficacy screening |
| Chemical | TAA | Chronic hepatotoxic exposure | Progressive fibrosis, cirrhosis | 6–12 weeks | Long-term fibrosis studies |
| Surgery | BDL | Surgical bile duct ligation | Cholestasis, portal fibrosis | 2–4 weeks | Biliary fibrosis research |
Endpoints
Creative Bioarray provides integrated multi-level endpoint analysis for comprehensive evaluation of liver fibrosis progression, therapeutic efficacy, and disease mechanisms.
Histopathology Analysis
- H&E staining
- Masson's trichrome staining
- Sirius Red staining
Serum Biochemistry
- ALT and AST
- Albumin and bilirubin
- Triglycerides and cholesterol
Fibrosis Biomarkers
- α-SMA
- COL1A1
- TGF-β
- TIMP-1
- Hydroxyproline
- Fibronectin
Molecular & Mechanistic Analysis
- Cytokine profiling
- Kupffer cell activation
- Oxidative stress markers
- qPCR / Western blot
- IHC / IF
Metabolic Evaluation
- Glucose tolerance
- Insulin resistance
- Liver/body weight ratio
Why Choose Creative Bioarray for Liver Fibrosis Studies
Broad Model Coverage Validated Liver Fibrosis Models
Well-established chemical-induced and surgical bile duct ligation (BDL) models to support diverse liver fibrosis research needs.
Human-Relevant Disease Modeling
Models recapitulate key pathological features of liver fibrosis, including hepatic injury, inflammation, extracellular matrix deposition, and fibrogenic activation.
Integrated Multi-Level Analysis
Comprehensive evaluation through histopathology, fibrosis-related biomarkers, and molecular pathway analysis for reliable efficacy and mechanism assessment.
Flexible CRO Study Design
Custom experimental design for efficacy, mechanism, biomarker, and PK/PD studies.
FAQ
What is the most popular animal model of liver fibrosis?
The CCl4-induced liver fibrosis model is one of the most commonly utilized preclinical models because it is reproducible, has a strong fibrosis phenotype and is useful for screening anti-fibrotic drugs.
What are the differences between CCl4 and BDL liver fibrosis models?
CCl4 models are mostly mimicking toxin caused hepatocellular injury and diffuse fibrosis while BDL models are mimicking cholestatic liver injury with substantial periportal fibrosis and bile duct proliferation.
What are the common endpoints in liver fibrosis efficacy studies?
Typical end points include histology, quantification of collagen, measurement of ALT/AST, hydroxyproline analysis, inflammatory cytokines, and fibrosis-related molecular markers such as α-SMA and TGF-β.
Contact Us
Creative Bioarray provides customized liver fibrosis CRO services for preclinical drug discovery, efficacy evaluation, and mechanistic research. Our scientific team supports study design, model selection, biomarker analysis, and integrated in vivo pharmacology solutions.
Contact us to discuss your liver fibrosis animal model
Reference
- Weiskirchen R, Weiskirchen S, et al. Recent advances in understanding liver fibrosis: bridging basic science and individualized treatment concepts. F1000research. 2018 ;7:F1000